Oireachtas Health Committee seek age restrictions on e-cigarettes and ban on flavourings

Regulations
Jul.19.2022
The committee asked the Minister for Health to look at other countries where ages for vaping and smoking are 21.

A BAN ON flavoured e-cigarettes, e-cigarette ads on social media and bright packaging are just some of the restrictions recommended in a report on pre-legislative scrutiny on a  public health bill published on the weekend.

Oireachtas Health Committee seek age restrictions on e-cigarettes and ban on flavourings

 

The Oireachtas joint committee on health compiled suggestions for the Public Health (Tobacco and Nicotine Inhaling Products) Bill 2019 after meeting with health specialists and representatives of the vaping industry.

 

A key recommendation was that the bill should regulate the flavouring of e-cigarettes and that all flavours except for tobacco, should be strictly prohibited so as not to entice minors.

 

Speaking to the committee, the Irish Heart Foundation called e-cigarette flavours marketing tools “that are almost exclusively directed at young people because if young people are not addicted, there is no business model.”

 

The committee has stated that the Minister for Health should review international studies to consider increasing the age for buying tobacco and nicotine-inhaling products  to 21.

 

Also giving evidence to the committee, the Royal College of Physicians in Ireland (RCPI) stated that teenagers are more likely to use flavoured nicotine products than other age groups.

 

However, the RCPI also told the committee that a recent study examining the effects of a similar ban in Finland did not report a significant change in e-cigarette use post introduction.

 

Many of the proposals made by the committee indicate a desire to treat e-cigarettes more like traditional cigarettes, such as a move to introduce plain packaging rather than what the Irish Cancer Society has called “cartoon-type packaging”.

 

According to a 2019 European School Survey Project on Alcohol and Other Drugs (ESPAD) vaping among young people is now more common than smoking and more young people aged 12-17 years have tried vaping (22%) compared to adults (14%).

 

The survey also found that in 15 and 16 year olds, almost four in 10 students (39%) had tried e-cigarettes and almost one in 5 (18%) were current users.

 

However, the sale of e-cigarettes to under-18s is still not against the law despite the fact that public health officials as well as representatives of the vaping industry have been advocating for it for years.

 

In response to the report’s publication Vape Business Ireland stated that the complexity of the suggestions would only delay the bill and the under-18s ban.

 

It also claimed that the committee referred to “outdated evidence, as well as research which falls short of international standards”.

 

Another measure in the report would ban the sale of e-cigarettes from temporary units such as kiosks, stalls or marquees at festivals and introduce a license for approved sellers.

 

The report also urges that the bill  contain measures to ban all forms of e-cigarette advertising on billboards, online on all social media platforms, and influencer marketing methods.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
EU ‘TPD3’ Enters Next Phase on Aug. 14 as Fragmented Vape and Nicotine Pouch Rules Push the Single Market Toward Regulatory Overhaul
A 12-week European Commission consultation on revising the Tobacco Products Directive and Tobacco Advertising Directive is due to close on Aug. 14, 2026. The Commission has identified e-cigarette flavours, disposable vapes, tobacco heating devices, nicotine pouches, nicotine-free e-cigarettes, packaging and digital marketing among areas for possible new EU rules. National regulations already vary significantly across the bloc, a fragmentation the Commission says creates internal-market barriers and distorts competition. No formal revised TPD/TAD legislative text has yet been published, with the Commission currently indicating December 2026 for the legislative initiative.
Aug.14
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
How Many Nicotine Pouch Factories Does Europe Need? 2Firsts Interviews AIRSCREAM on the OEM Market
At InterTabac 2026, nicotine pouch growth was visible not only in brands but across equipment, raw materials and OEM manufacturing. 2Firsts interviewed AIRSCREAM commercial head Steve Moore on how many pouch factories Europe may ultimately need and where manufacturers can differentiate, from formulation and flavour to pouch materials, production consistency and customer service. The category continues to expand, but questions remain over future capacity, consolidation and the long-term structure of the supply chain.
Sep.18
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08